NASDAQ$AMGN
Amgen Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Amgen's Q4 2022 financial results were reported, showing stable revenues and declining earnings per share.
Amgen's Q4 2022 revenues remained largely unchanged at $6.8 billion, while GAAP EPS decreased by 11% to $3.00 and non-GAAP EPS decreased by 7% to $4.09. The company's product sales benefited from a 10% volume growth, offset by lower net selling prices and foreign exchange impacts.
- Total revenues were $6.8 billion, largely unchanged from Q4 2021.
- GAAP earnings per share (EPS) decreased 11% from $3.36 to $3.00.
- Non-GAAP EPS decreased 7% from $4.40 to $4.09.
- Product sales increased 4%, driven by 10% volume growth, partially offset by lower net selling price and foreign exchange impacts.
Headline financials
Revenue & EPS history
Amgen · Revenue · Quarterly
$6.84B
Revenue by segment
Amgen · $6.15B total across 18 segments · Q4 2022
- Enbrel$1.1B-0.9%17.9%
- Prolia$992M+13.6%16.1%
- Otezla$616M-2.2%10.0%
- XGEVA$484M-11.2%7.9%
- Nplate$469M+66.3%7.6%
- Aranesp$348M-3.9%5.7%
- Repatha$333M+22.0%5.4%
- KYPROLIS$325M+14.4%5.3%
- Vectibix$238M-2.1%3.9%
- EVENITY$225M+57.3%3.7%
- Neulasta$221M-37.0%3.6%
- MVASI$205M-32.6%3.3%
- BLINCYTO$164M+24.2%2.7%
- AMJEVITA/AMGEVITA$119M+3.5%1.9%
- Other products$119M+12.3%1.9%
- Parsabiv$93M+34.8%1.5%
- TEZSPIRE$79M—1.3%
- TAVNEOS$21M—0.3%
Forward guidance
For the full year 2023, excluding any contribution from the announced acquisition of Horizon Therapeutics, the Company expects: •Total revenues in the range of $26.0 billion to $27.2 billion. •On a GAAP basis, EPS in the range of $13.16 to $14.41, and a tax rate in the range of 17.0% to 18.5%. •On a non-GAAP basis, EPS in the range of $17.40 to $18.60, and a tax rate in the range of 18.0% to 19.0%. •Capital expenditures to be approximately $925 million. •Share repurchases not to exceed $500 million.
Tailwinds
- Total revenues in the range of $26.0 billion to $27.2 billion.
- GAAP EPS in the range of $13.16 to $14.41
- GAAP tax rate in the range of 17.0% to 18.5%.
- Non-GAAP EPS in the range of $17.40 to $18.60
- Non-GAAP tax rate in the range of 18.0% to 19.0%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.3%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+0.1%
Avg return
30 days after
53%
39 / 73 earnings
Positive
+12.2%
Q1 2024
Best reaction
-8.7%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | -4.4% | -2.7% | |
| Q4 2025 | +3.0% | +11.0% | +9.1% | |
| Q3 2025 | +7.7% | +9.1% | +11.2% | |
| Q2 2025 | -5.1% | -5.0% | -5.5% | |
| Q1 2025 | -1.1% | -2.8% | +1.6% | |
| Q4 2024 | +6.5% | +2.0% | +12.4% | |
| Q3 2024 | +1.3% | +0.3% | -10.5% | |
| Q2 2024 | -3.9% | -0.8% | -0.3% | |
| Q1 2024 | +12.2% | +8.3% | +10.3% | |
| Q4 2023 | -8.1% | -9.6% | -15.3% | |
| Q3 2023 | -0.9% | +2.5% | +2.5% | |
| Q2 2023 | +5.6% | +13.2% | +11.4% | |
| Q1 2023 | +0.4% | -1.2% | -9.2% | |
| Q4 2022 | -2.1% | -2.6% | -6.7% | |
| Q3 2022 | +0.0% | +8.7% | +6.1% | |
| Q2 2022 | -0.4% | +0.5% | -1.9% | |
| Q1 2022 | -4.7% | -7.6% | +2.2% | |
| Q4 2021 | +8.5% | +2.7% | +4.2% | |
| Q3 2021 | +4.0% | +1.9% | -4.1% | |
| Q2 2021 | -4.8% | -4.0% | -5.8% | |
| Q1 2021 | -7.4% | -6.2% | -7.9% | |
| Q4 2020 | -1.4% | -1.7% | -7.7% | |
| Q3 2020 | -2.5% | -1.5% | +0.6% | |
| Q2 2020 | -1.9% | -3.5% | -0.3% | |
| Q1 2020 | -2.0% | +0.3% | -2.5% | |
| Q4 2019 | -4.9% | -2.4% | -12.1% | |
| Q3 2019 | +2.9% | +6.3% | +14.4% | |
| Q2 2019 | +6.0% | +6.3% | +17.5% | |
| Q1 2019 | -2.8% | -2.1% | -6.7% | |
| Q4 2018 | -3.7% | -2.5% | -1.0% | |
| Q3 2018 | +2.4% | -0.6% | +7.5% | |
| Q2 2018 | -0.3% | +1.8% | +1.9% | |
| Q1 2018 | +0.1% | +1.6% | +1.9% | |
| Q4 2017 | +0.5% | -5.1% | -0.5% | |
| Q3 2017 | -2.1% | -3.2% | -5.7% | |
| Q2 2017 | -2.9% | -3.6% | -6.1% | |
| Q1 2017 | -1.2% | -1.3% | -5.9% | |
| Q4 2016 | +4.9% | +4.5% | +12.9% | |
| Q3 2016 | -8.7% | -11.5% | -8.5% | |
| Q2 2016 | +2.2% | +3.9% | +2.6% | |
| Q1 2016 | -1.7% | — | — | |
| Q4 2015 | +1.5% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +3.0% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q3 2014 | +6.7% | — | — | |
| Q2 2014 | +6.0% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +1.8% | — | — | |
| Q2 2013 | -1.0% | — | — | |
| Q1 2013 | -7.5% | — | — | |
| Q4 2012 | -0.8% | — | — | |
| Q3 2012 | +0.8% | — | — | |
| Q2 2012 | +7.6% | — | — | |
| Q1 2012 | +0.2% | — | — | |
| Q4 2011 | -0.8% | — | — | |
| Q3 2011 | +4.9% | — | — | |
| Q2 2011 | -3.0% | — | — | |
| Q1 2011 | -1.5% | — | — | |
| Q4 2007 | +0.7% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2008 | +0.7% | — | — | |
| Q3 2010 | -0.9% | — | — | |
| Q2 2010 | -0.4% | — | — | |
| Q1 2009 | +1.5% | — | — | |
| Q1 2010 | +1.2% | — | — | |
| Q4 2009 | +0.5% | — | — | |
| Q3 2009 | +1.6% | — | — | |
| Q4 2008 | +3.8% | — | — | |
| Q2 2009 | +3.8% | — | — | |
| Q2 2008 | +3.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro